drugset / Trial / NCT03582618
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.
Timeline
- Start
- 2018-07-12
- Primary completion
- 2021-11-16
- Completion
- 2022-12-30
Outcome
Outcome not reported
Stopped (Enrollment): “The study has been terminated due to slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVM-1118 | Small molecule | 150 mg | Oral |
| Subject | CVM-1118 | Small molecule | 200 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |